pharmaceutical investing Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
